The Goldman Sachs Group Issues Positive Forecast for Gossamer Bio (NASDAQ:GOSS) Stock Price

Gossamer Bio (NASDAQ:GOSS) had its price objective increased by The Goldman Sachs Group from $7.00 to $8.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Wedbush reissued an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research note on Tuesday, March 18th.

Gossamer Bio Trading Down 1.0%

GOSS opened at $1.04 on Friday. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55. The stock has a market capitalization of $236.31 million, a price-to-earnings ratio of -3.25 and a beta of 1.82. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The business has a fifty day moving average price of $1.04 and a 200 day moving average price of $0.99.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The company had revenue of $9.89 million for the quarter, compared to analyst estimates of $3.95 million. Sell-side analysts expect that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

A number of institutional investors have recently bought and sold shares of GOSS. Octagon Capital Advisors LP lifted its holdings in Gossamer Bio by 99.7% during the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock worth $16,599,000 after buying an additional 9,162,117 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in Gossamer Bio by 52.7% during the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after buying an additional 3,041,058 shares during the last quarter. Monaco Asset Management SAM lifted its holdings in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after buying an additional 1,520,721 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock worth $1,034,000 after buying an additional 825,047 shares during the last quarter. Finally, Allostery Investments LP purchased a new stake in Gossamer Bio during the 4th quarter worth about $555,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.